Insulet (MEX:PODD) Current Accrued Expense: MXN10,504 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:PODD Insulet Corp MEX:PODD
81 GF Score
Price MXN2,780.00
GF Value MXN7,333.17
View Full Analysis

What is Insulet Current Accrued Expense?

Insulet MEX:PODD 81 Current Accrued Expense is MXN10,504 Mil as of Jun. 2026. GuruFocus rates MEX:PODD with a GF Score™ of 81/100 and a GF Value™ of MXN7,333.17.

Insulet's Current Accrued Expense for the quarter that ended in Jun. 2026 was MXN10,504 Mil.

Insulet's quarterly Current Accrued Expense increased from Dec. 2025 (MXN4,748 Mil) to Mar. 2026 (MXN9,359 Mil) and increased from Mar. 2026 (MXN9,359 Mil) to Jun. 2026 (MXN10,504 Mil).

Insulet's annual Current Accrued Expense increased from Dec. 2023 (MXN3,174 Mil) to Dec. 2024 (MXN4,190 Mil) and increased from Dec. 2024 (MXN4,190 Mil) to Dec. 2025 (MXN4,748 Mil).

Insulet Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Insulet's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insulet Current Accrued Expense Chart

Insulet Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,913.96 3,115.46 3,174.18 4,189.91 4,748.10

Insulet Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,055.47 6,367.27 4,748.10 9,358.97 10,504.30
MEX:PODD
81GF Score
Insulet Corp MEX:PODD
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insulet Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of MXN10,504 Mil mean?
Insulet (MEX:PODD) has a Current Accrued Expense of MXN10,504 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Insulet and its competitors.
Is Insulet's Current Accrued Expense too high?
Insulet's current Current Accrued Expense is MXN10,504 Mil. Overall, Insulet has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does Insulet's Current Accrued Expense compare to BIO and GKOS?
Insulet's Current Accrued Expense of MXN10,504 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Devices & Instruments company?
A good Current Accrued Expense depends on the Medical Devices & Instruments industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Insulet and its competitors. Insulet's current Current Accrued Expense is MXN10,504 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insulet stock overvalued right now?
Insulet (MEX:PODD) has a current Current Accrued Expense of MXN10,504 Mil. The stock's GF Value™ is MXN7,333.17, compared to a current price of MXN2,780.00 — trading 62.1% below its estimated fair value. The current Current Accrued Expense is MXN10,504 Mil. Insulet's overall GF Score™ is 81/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Insulet (MEX:PODD), the current Current Accrued Expense is MXN10,504 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insulet (MEX:PODD) Overvalued in 2026?

Based on GuruFocus' analysis, Insulet stock appears to be undervalued. The current stock price of MXN2,780.00 is trading 62.1% below its estimated GF Value™ of MXN7,333.17.

Key valuation signals for MEX:PODD:

  • Current Accrued Expense: MXN10,504 Mil
  • GF Value™: MXN7,333.17 vs. price of MXN2,780.00 (62.1% below fair value)
  • GF Score™: 81/100

No single metric tells the full story. See the MEX:PODD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insulet Business Description

Address 100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
81GF Score

Get the complete analysis for MEX:PODD

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,780.00
Price
MXN7,333.17
GF Value